Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485814 | 0.84 | ALDH1A1 (0.54) | POLBRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2488317 | 0.81 | NPC1 (0.62) | POLBRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL18883276 | 0.80 | ALDH1A1 (0.56) | POLBRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2087968 | 0.79 | PTGS1 (0.51) | RAB9ASMN1; SMN2NPC1ALDH1A1MEN1 | |
| SCHEMBL2085892 | 0.79 | RAB9A (0.50) | POLBRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| Bromide SCHEMBL2087132 | 0.77 | PTGS1 (0.50) | RAB9ASMN1; SMN2NPC1ALDH1A1MEN1 | |
| SCHEMBL1728496 | 0.77 | PTGS1 (0.50) | RAB9ASMN1; SMN2NPC1APPKMT2A | |
| SCHEMBL2086460 | 0.77 | PTGS1 (0.50) | CYP2C9PTGS1PTGS2 | |
| SCHEMBL2086415 | 0.77 | RXFP1 (0.47) | RAB9ASMN1; SMN2NPC1ALDH1A1APP | |
| SCHEMBL2087802 | 0.77 | PTGS1 (0.46) | RAB9ANPC1KMT2ACYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902219-B2 | 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-08 | — | — | US | disclosed |
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | NR4A2, NR4A3, NCOR1 | POLB 3459/4885RAB9A 3310/4885SMN1; SMN2 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.